Rokit 4D Bioprinting and DFU/Skin Regeneration

发表时间 :2020-01-30 作者 :Admin

16_Rokit_award.jpg

Learn more about the 2019 PharmSci 360 Tech Challenge winner.– AAPS Newsmagazine

The 2019 winner of the first-ever Tech Challenge during PharmSci 360 was Jeehee Kim, Ph.D., for ROKIT Healthcare. Four companies participated in 20-minute presentations followed by 10-minute Q&As to showcase their latest breakthrough technology. Each presentation was scored by their peer judges on the criteria of practicality, applicability, and innovation. Kim presented new technology in tissue engineering and organ regeneration.

“Since 4D biofabricating technology is the best way to recapitulate the complex and functional human body,” explained Kim in her Tech Challenge application, “we have developed the therapeutic 4D bioprinter called Dr.INVIVO to use in tissue engineering and/or human organ regeneration.”

Kim receives Tech Challenge award from AAPS President Joseph W. Polli during the PharmSci 360 closing session.

“To find an advanced medical solution, particularly for diabetic wound healing and skin regeneration, we have tested the 4D bioprinting application with the minimally manipulated autologous fat tissue in clinical study. The extracellular matrix (ECM) derived from nano-fat consisting of variety of proteins, including growth factors and cytokines, has been reported as an important player to provide efficient three dimensional environments during cell proliferation and differentiation. Therefore, we hypothesized that ROKIT’s 4D bioprinting technology of the minimally manipulated ECM (MA-ECM) could be an alternative treatment solution to promote the mechanism of skin reconstruction. During the clinical test, most of the patients with diabetic foot ulcer (DFU) showed significant reduction in wound size with distinct epithelization process for an average of 4 weeks after only one-time treatment of MA-ECM. In addition, the appropriate design of bio-inks and biomaterials can promise the effective customized 4D bioprinting system to regenerate human tissue and organs.”

KakaoTalk_20200130_171933952.jpg

Jeehee Kim received her doctorate from Maximillian Ludwig University of Munich, Germany, and she is the president of the DFU & Skin Regeneration Strategy Business Unit at ROKIT Healthcare.

Dr.INVIVO is the world’s first sterile, all-in-one 4D organ regenerator. ROKIT’s autologous skin regeneration procedure using Dr.INVIVO has received regulatory approval for non-advanced therapy medicinal product (ATMP), meaning immediate access to the operating room (May 2019) by the European Medicines Agency (EMA) for the treatment of: 1) diabetic ulcer, 2) pressure ulcer, 3) scar revision, and 4) burn wound.


rokit_logo_newArtboard-11x.png

罗吉特医疗保健是一家位于韩国的从事4D生物打印和生物技术的公司,致力于通过我们在再生医学领域的贡献而改善人类。

有用的链接

公司介绍

公司新闻

联系我们

企业注册号码

图层 3.png

119-86-51995

联系方式

形状 3.png

大韩民国,首尔特别市,衿川区, 加山洞,10路数码路9,12层,08514

形状 4.png

china@rokit.co.kr

形状 5.png

+86-13512263495

Copyright © 2019 ROKIT HEALTHCARE All Rights Reserved Terms of Use and Privacy Policy

12F, 9, Digital-ro 10-gil, Geumcheon-gu (Highhill Bldg, Gasan-dong), Seoul, Republic of Korea, 08514, COMPANY : ROKIT Healthcare, COMPANY # : 119-86-51995, CEO :  Seok Hwan You